Bisoprolol and magnesium medications in arterial hypertension treatment

Abstract

Aim. To investigate therapeutic efficacy of selective beta-1-adrenoblockers combined with magnesium (Mg) medications, in the treatment of arterial hypertension (AH), as well as their role in blood rheology normalization: effects on platelet aggregation activity (APl), red blood cell electrophoretic mobility (RBC EPM), lipid profile, serum and RBC Mg levels. Material and methods. One hundred patients were examined: 20 normotensives (mean age 53.1±5.8 years), and 80 hypertensives with Stage I-II AH (mean age 51.41±6.3 years). Mg deficit – RBC Mg concentration <1.6 mmol/l – was observed in 32 AH patients (40%; subgroup A). Subgroup B included 48 hypertensive individuals with RBC Mg concentration >1.6 mmol/l. Bisoprolol monotherapy (7.5±0.15 mg/d) lasted for 6 months. In subgroup A, bisoprolol was combined with Mg medication. Results. By the end of the treatment, there was a decrease of systolic blood pressure (SBP) by 15%, and diastolic blood pressure (DBP) by 21.3% in subgroup A. In subgroup B, SBP declined by 13.3%, DBP – by 16.3%. RBC Mg concentration correlated with SBP and DBP levels. After 6 months of treatment, APl declined by 31.8% and 19% in subgroups A and B, respectively (р<0.05). There was a strong positive correlation between APl and BP level. RBC EPM increased by 19.7% (p<0.05) and 11.1% (p<0.05) in subgroups A and B, respectively. RBC EPM correlated with BP level, RBC Mg concentration, and plasma atherogenity index (AI). AI decreased by 50.6%, due to reduced triglycerides (-15.1%) and low-density lipoprotein cholesterol (-40.9%) levels, and increased high-density lipoprotein cholesterol levels (+30.6%) (p<0.01). Conclusion. Bisoprolol, combined with Mg medications in AH treatment program, decreased APl, AI, increased RBC EPM, that resulted in SBP and DPB levels normalization.

Keywords

• arterial hypertension
• therapeutic education
• treatment compliance